Rare pediatric diseases are getting a boost from Alexion Pharmaceuticals, who recently announced a research collaboration with Cincinnati Children's Hospital Medical Center.
Researchers at the University of Wisconsin-Madison and Cellectar Biosciences have improved the safety of broad-spectrum cytotoxic drugs by engineering molecules that specifically target malignant cells. The key was exploiting differences in lipid architecture between the two types of cells.
Hedgehog-mediated degradation of chemotherapeutics is a key resistance mechanism in AML, according to findings from Canadian researchers. Their next step is clinical testing of a chemotherapy-hedgehog antagonist combination.